Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Assets (2016 - 2025)

Historic Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $1.2 billion.

  • Arrowhead Pharmaceuticals' Current Assets rose 10583.96% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 10583.96%. This contributed to the annual value of $950.6 million for FY2025, which is 3669.0% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Current Assets is $1.2 billion, which was up 10583.96% from $950.6 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Current Assets high stood at $1.2 billion for Q4 2025, and its period low was $237.9 million during Q4 2023.
  • Its 5-year average for Current Assets is $591.5 million, with a median of $533.8 million in 2021.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Current Assets tumbled by 5862.62% in 2023, and later soared by 13982.28% in 2024.
  • Arrowhead Pharmaceuticals' Current Assets (Quarter) stood at $338.3 million in 2021, then soared by 69.98% to $575.0 million in 2022, then tumbled by 58.63% to $237.9 million in 2023, then surged by 139.82% to $570.5 million in 2024, then skyrocketed by 105.84% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $950.6 million for Q3 2025, and $946.9 million during Q2 2025.